Nivolumab plus PAI-1 inhibitor combined therapy for unresectable advanced melanoma: Phase II clinical trial

被引：0
|
作者：
Fujimura, T. [1 ]
Yoshino, K. [2 ]
Kato, H. [3 ]
Fukushima, S. [4 ]
Otsuka, A. [5 ]
Matsushita, S. [6 ]
Fujisawa, Y. [7 ]
Ishizuki, S. [8 ]
Kambayashi, Y. [1 ]
Asano, Y. [1 ]
机构：
[1] Tohoku Daigaku, Dermatol, Sendai, Miyagi, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dermato Oncol, Tokyo, Japan
[3] Nagoya Shiritsu Daigaku, Dermatol, Nagoya, Aichi, Japan
[4] Kumamoto Daigaku, Dept Dermatol, Kumamoto, Kumamoto, Japan
[5] Kinki Daigaku, Dept Dermatol, Higashiosaka, Osaka, Japan
[6] Kokuritsu Byoin Kiko Kagoshima Iryo Ctr, Dermato Oncol, Kagoshima, Kagoshima, Japan
[7] Ehime Daigaku, Dermatol, Matsuyama, Ehime, Japan
[8] Tsukuba Daigaku, Dermatol, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1194
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [31] Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
    Tong, Thais M. L.
    Burgmans, Mark C.
    Van der Kooij, Monique
    Speetjens, Frank M.
    van Erkel, Arian R.
    van der Meer, Rutger W.
    van den Bosch, Shelley
    Jonker, Mare A.
    Roozen, Inge C. F. M.
    Lutjeboer, Jacob
    Rijksen, Fenna
    van Persijn-van Meerten, Els L.
    Martini, Chris H.
    Zoethout, Remco W. M.
    Tijl, Fred G. J.
    Blank, Christian U.
    Kapiteijn, Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
    Tong, T. M. L.
    van der Kooij, M. K.
    Speetjens, F. M.
    van Erkel, A. R.
    van der Meer, R. W.
    Lutjeboer, J.
    van Meerten, E. L. van Persijn
    Martini, C. H.
    Zoethout, R. W. M.
    Tijl, F. G. J.
    Blank, C. U.
    Burgmans, M. C.
    Kapiteijn, E.
    TRIALS, 2022, 23 (01)
  • [33] Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial A randomized clinical trial of neoadjuvant therapy for ESCC
    Li, Yong
    Zhou, Aiping
    Liu, Shuoyan
    He, Ming
    Chen, Keneng
    Tian, Ziqiang
    Li, Yin
    Qin, Jianjun
    Wang, Zhen
    Chen, Haiquan
    Tian, Hui
    Yu, Yue
    Qu, Wang
    Xue, Liyan
    He, Shun
    Wang, Shuhang
    Bie, Fenglong
    Bai, Guangyu
    Zhou, Bolun
    Yang, Zhaoyang
    Huang, Huiyao
    Fang, Yan
    Li, Benjamin
    Dai, Xiangrong
    Gao, Shugeng
    He, Jie
    BMC MEDICINE, 2023, 21 (01)
  • [34] Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma
    Bedikian, AY
    Legha, SS
    Eton, O
    Buzaid, AC
    Papadopoulos, N
    Coates, S
    Simmons, T
    Neefe, J
    vonRoemeling, R
    ANNALS OF ONCOLOGY, 1997, 8 (04) : 363 - 367
  • [35] Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis
    Anouti, Bilal
    McVay, Krysta
    Abraham, Manjusha
    Johnson, Daniel H.
    Amaria, Rodabe Navroze
    Spillson, Christine
    Glitza, Isabella Claudia
    Patel, Sapna Pradyuman
    Wong, Michael K. K.
    McQuade, Jennifer Leigh
    Tawbi, Hussein A.
    Davies, Michael A.
    Ikeguchi, Alexandra
    Bentebibel, Salah-Eddine
    Abdel-Wahab, Reham
    Elsayes, Khaled M.
    Allison, James Patrick
    Sharma, Padmanee
    Abdel-Wahab, Noha
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in BRCA or BRCA-ness
    Isaacs, James
    Sussman, Tamara A.
    Kennedy, Lucy B.
    Arbesman, Joshua
    Gastman, Brian
    Zhou, Millennia
    Zabor, Emily
    Diaz-Montero, Claudia
    Ko, Jennifer
    Funchain, Pauline
    CANCER RESEARCH, 2024, 84 (07)
  • [37] Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S679 - S680
  • [38] 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanoma
    Larkin, J. M. G.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Rutkowski, P.
    Lao, C.
    Cowey, C. L.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hogg, D.
    Hill, A.
    Marquez-Rodas, I.
    Haanen, J. B. A. G.
    Rizzo, J.
    Balogh, A.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 904 - 905
  • [39] Interim results from a phase I/II study of duvelisib PI3Kdg inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
    Jin, Jingxiao
    Rohatgi, Anjali
    Gabrielle, Andrew
    Rose, Amy
    Wilson, Melissa
    Bruno, Tullia C.
    Kirkwood, John M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
    Lau, Peter Kar Han
    Harris, Samuel John
    Eastgate, Melissa A.
    Kee, Damien
    Mant, Andrew
    Nott, Louise M.
    Gedye, Craig
    Inderjeeth, Andrisha Jade
    Underhill, Craig
    Weppler, Alison Margaret
    Wallace, Roslyn
    Lee, Belinda
    Au-Yeung, George
    Williams, Narelle
    Ospino, Daniel Ariza
    Gonzales, Louise
    Shackleton, Mark J.
    Lo, Serigne N.
    McArthur, Grant A.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345